ArticleNeurology(R) neuroimmunology & neuroinflammation2026
Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTo investigate the association between serum levels of glial-related biomarkers, including glycoprotein nonmetastatic melanoma B (GPNMB), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), galectin-3, serpin peptidase inhibitor clade A member 3 (SERPINA3), chitotriosidase-1 (CHIT1), and chitinase 3-like 1 (CHI3L1) and 2 (CHI3L2), and the presence of paramagnetic rim lesions (PRLs) and the risk of progression independent of relapse activity (PIRA) in patients with a first demyelinating event.
methodsPRLs were identified using 3T susceptibility-based imaging. Univariable and multivariable linear regression models assessed the association between biomarker levels and the presence of PRLs at baseline. Univariable and multivariable Cox proportional hazards models investigated the association between biomarker levels and risk of PIRA during follow-up. sTREM2 and CHI3L1 levels were measured using single molecule array assays, whereas levels of the remaining biomarkers were determined using ELISA.
resultsWe included 135 patients (median age, 34.4 [interquartile range (IQR) 29.2-41.7] years; 98 [72.6%] women; median follow-up, 5.4 [IQR 2.7-9.4] years). PRLs were detected in 59 (43.7%) patients. The presence of ≥1 PRLs at baseline was associated with increased levels of CHI3L1 in univariable (multiplicative effect [ME] = 1.32; 95% CI 1.10-1.58; DISCUSSION: These findings suggest distinct contributions of glial-related biomarkers to radiologic and clinical outcomes in early multiple sclerosis. Validation in independent cohorts will be required before their value as blood prognostic biomarkers can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.